Results 1 to 10 of about 6,989 (168)

PARG regulates the proteasomal degradation of TARG1 [PDF]

Cell Reports
Summary: ADP-ribosylation (ADPr) is a reversible modification of macromolecules critical for the regulation of genome stability, stress responses, and proteostasis.
Joséphine Groslambert, Sara C. Buch-Larsen, Ivo A. Hendriks, Robert Kurzbauer, Jonas D. Elsborg, Chatrin Chatrin, Thomas Agnew, Callum Henfrey, Michael Tellier, Evgeniia Prokhorova, Song My Hoang, Jonathan Barosso-Gonzalez, Roderick J. O’Sullivan, Tim Clausen, Michael L. Nielsen, Ivan Ahel   +15 more
doaj   +4 more sources

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP‐ribose) glycohydrolase inhibitor [PDF]

FEBS Open Bio
Poly(ADP‐ribose) glycohydrolase (PARG) is a key enzyme involved in poly(ADP‐ribose) (PAR) degradation and is considered a potential anticancer target. We previously investigated resistance mechanisms to the PARG inhibitor PDD00017273 in human colorectal ...
Kaede Tsuda, Yoko Ogino, Akira Sato
doaj   +3 more sources

PARG Mutation Uncovers Critical Structural Determinant for Poly(ADP-Ribose) Hydrolysis and Chromatin Regulation in Embryonic Stem Cells [PDF]

Cells
Poly(ADP-ribosyl)ation is a crucial posttranslational modification that governs gene expression, chromatin remodeling, and cellular homeostasis. This dynamic process is mediated by the opposing activities of poly(ADP-ribose) polymerases (PARPs), which ...
Alexei Tulin, Guillaume Bordet
exaly   +4 more sources

Loss‐of‐function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5‐fluorouracil and irinotecan treatment in colorectal cancer [PDF]

Clinical and Translational Medicine
Background Colorectal cancer (CRC) remains a major global health concern, partly due to resistance to therapy and the lack of new effective treatments for advanced disease.
Cristina Queralt, Cristina Moreta‐Moraleda, Marta Costa, Ferran Grau‐Leal, Jeannine Diesch, Carla Vendrell‐Ayats, Eva Musulén, Roni H G Wright, Cristina Bugés, José Luis Manzano, Sara Cabrero‐de las Heras, Johannes Zuber, Marcus Buschbeck, Sonia‐V Forcales, Eva Martínez‐Balibrea   +14 more
doaj   +2 more sources

Poly(ADP-ribose) glycohydrolase enforces p21 degradation via dePARylation to promote gastric cancer progression [PDF]

The Journal of Clinical Investigation
Dysregulation of cell cycle checkpoints is a cancer hallmark, with ubiquitination-controlled protein stability playing a pivotal role. Although p21, a key cyclin-dependent kinase inhibitor, is tightly regulated by ubiquitin-mediated degradation, the key ...
Yangchan Hu, Qimei Bao, Yixing Huang, Yan Wang, Xin Zhao, Junjun Nan, Yuxin Meng, Mingcong Deng, Yuancong Li, Zirui Zhuang, Hanyi He, Dan Zu, Yuke Zhong, Chunkai Zhang, Bing Wang, Ran Li, Yanhua He, Qihan Wang, Min Liu, John A. Tainer, Yin Shi, Xiangdong Cheng, Ji Jing, Zu Ye   +23 more
doaj   +2 more sources

FET proteins and PARylation-dependent condensates promote replication fork reversal and genome stability [PDF]

Nature Communications
Targeting replication-associated DNA repair mechanisms, including the control of ADP-ribosylation by PARP1/2 and PARG, is a powerful therapeutic approach for cancer. However, the mechanisms by which PARG inhibition impacts DNA replication remain unclear.
Celeste Giansanti, Jack C. Schultz, Jessica Jackson, Alessandro Vindigni, David Cortez   +4 more
doaj   +2 more sources

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair

EMBO Journal
Targeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make cancer cells susceptible to such a ...
Hendrik Johannes Kuiken, Jos Jonkers, Sven Rottenberg   +2 more
exaly   +2 more sources

PARG inhibition in ATM-deficient prostate cancer: from mechanistic discovery to therapeutic potential [PDF]

Journal of Translational Medicine
Background ATM deficiency is frequently observed in castration-resistant prostate cancer (CRPC). However, effective therapeutic vulnerabilities associated with this genetic alteration remain poorly defined.
Xuan Zhou, Chunyu Guo, Zhiguo Fan, Yihaoyun Lou, Zhiying Yue, Weidong Xu, Zhixiang Xin, Shancheng Ren   +7 more
doaj   +2 more sources

PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination [PDF]

npj Breast Cancer
PARG plays an important role in cancer progression and immunoresponse, but its role in breast cancer is not yet fully elucidated. The advanced breast cancer is still a persistent challenge in clinical oncology.
Junnai Wang, Yanhua Dong, Weiwei Lun, Manman Nai, Yajing Shi, Jianfang Geng, Wenhui Cai, Jiaxi Liu, Hongyu Li, Lei Li   +9 more
doaj   +2 more sources

PARG inhibition reduces ssDNA levels and limits RPA loading upon replication fork collapse [PDF]

EMBO Reports
Poly(ADP-ribosyl)ation (PARylation) is a transient post-translational modification catalyzed by PARP enzymes and reversed by PARG. PARG inhibition causes sustained PARylation and is being explored as an anticancer strategy, but its cellular consequences ...
Alexandra Mihuț, Debanjan Ghosh, Adrián Kószó, Dávid Szüts, Sarka Andrs Salajkova, Martin Andrs, Jana Dobrovolna, Roberta Fajka-Boja, Gyula Timinszky   +8 more
doaj   +2 more sources